Targeted Delivery of c(RGDfk)‐Modified Liposomes to Bone Marrow Through In Vivo Hitchhiking Neutrophils for Multiple Myeloma Therapy

Abstract Multiple myeloma (MM) is a prevalent bone marrow disorder. The challenges in managing MM include selecting chemotherapy regimens that effectively modulate the myeloma microenvironment and delivering them to the bone marrow with high efficacy and minimal toxicity. Herein, a novel bone marrow...

Full description

Saved in:
Bibliographic Details
Main Authors: Huiwen Liu, Bo Zhang, Hongrui Chen, Honglan Wang, Xifeng Qin, Chunyan Sun, Zhiqing Pang, Yu Hu
Format: Article
Language:English
Published: Wiley 2025-03-01
Series:Advanced Science
Subjects:
Online Access:https://doi.org/10.1002/advs.202409895
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850277957626494976
author Huiwen Liu
Bo Zhang
Hongrui Chen
Honglan Wang
Xifeng Qin
Chunyan Sun
Zhiqing Pang
Yu Hu
author_facet Huiwen Liu
Bo Zhang
Hongrui Chen
Honglan Wang
Xifeng Qin
Chunyan Sun
Zhiqing Pang
Yu Hu
author_sort Huiwen Liu
collection DOAJ
description Abstract Multiple myeloma (MM) is a prevalent bone marrow disorder. The challenges in managing MM include selecting chemotherapy regimens that effectively modulate the myeloma microenvironment and delivering them to the bone marrow with high efficacy and minimal toxicity. Herein, a novel bone marrow targeting strategy using c(RGDfk) peptide‐modified liposomes loaded with chemotherapeutics is developed, which can specifically recognize and hitchhike neutrophils following systemic administration, capitalizing on their natural aging process to facilitate precise drug delivery to the bone marrow, thus minimizing off‐target effects. On the one hand, c(RGDfk)‐functionalized liposomes containing carfilzomib (CRLPs) successfully transformed macrophages from M2 phenotype to M1 phenotype, enhancing immunotherapeutic responses. On the other hand, c(RGDfk)‐functionalized liposomes encapsulating BMS‐202 (BRLPs), a small molecule checkpoint inhibitor, interrupted the PD‐1/PD‐L1 axis and promoted the infiltration of cytotoxic T cells. The co‐administration of CRLPs and BRLPs successfully delivered drugs to bone marrow, leading to significant modulation of the myeloma microenvironment, reduced tumor growth, and improved survival time of MM‐bearing mouse models. These findings introduced an alternative approach to modulating the myeloma microenvironment and underscored the efficacy of hitchhiking neutrophils for bone marrow drug delivery. This strategy show advantages over traditional drug delivery methods in terms of improved efficacy and lowered toxicity.
format Article
id doaj-art-d7c797ffb6f6408b8b831ab437270bd2
institution OA Journals
issn 2198-3844
language English
publishDate 2025-03-01
publisher Wiley
record_format Article
series Advanced Science
spelling doaj-art-d7c797ffb6f6408b8b831ab437270bd22025-08-20T01:49:41ZengWileyAdvanced Science2198-38442025-03-011212n/an/a10.1002/advs.202409895Targeted Delivery of c(RGDfk)‐Modified Liposomes to Bone Marrow Through In Vivo Hitchhiking Neutrophils for Multiple Myeloma TherapyHuiwen Liu0Bo Zhang1Hongrui Chen2Honglan Wang3Xifeng Qin4Chunyan Sun5Zhiqing Pang6Yu Hu7Institute of Hematology Union Hospital Tongji Medical College Huazhong University of Science & Technology Wuhan Hubei 430022 ChinaInstitute of Hematology Union Hospital Tongji Medical College Huazhong University of Science & Technology Wuhan Hubei 430022 ChinaDepartment of Pathology Union Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan 430022 ChinaInstitute of Hematology Union Hospital Tongji Medical College Huazhong University of Science & Technology Wuhan Hubei 430022 ChinaSchool of Pharmacy Fudan University Key Laboratory of Smart Drug Delivery Ministry of Education 826 Zhangheng Road Shanghai 201203 ChinaInstitute of Hematology Union Hospital Tongji Medical College Huazhong University of Science & Technology Wuhan Hubei 430022 ChinaSchool of Pharmacy Fudan University Key Laboratory of Smart Drug Delivery Ministry of Education 826 Zhangheng Road Shanghai 201203 ChinaInstitute of Hematology Union Hospital Tongji Medical College Huazhong University of Science & Technology Wuhan Hubei 430022 ChinaAbstract Multiple myeloma (MM) is a prevalent bone marrow disorder. The challenges in managing MM include selecting chemotherapy regimens that effectively modulate the myeloma microenvironment and delivering them to the bone marrow with high efficacy and minimal toxicity. Herein, a novel bone marrow targeting strategy using c(RGDfk) peptide‐modified liposomes loaded with chemotherapeutics is developed, which can specifically recognize and hitchhike neutrophils following systemic administration, capitalizing on their natural aging process to facilitate precise drug delivery to the bone marrow, thus minimizing off‐target effects. On the one hand, c(RGDfk)‐functionalized liposomes containing carfilzomib (CRLPs) successfully transformed macrophages from M2 phenotype to M1 phenotype, enhancing immunotherapeutic responses. On the other hand, c(RGDfk)‐functionalized liposomes encapsulating BMS‐202 (BRLPs), a small molecule checkpoint inhibitor, interrupted the PD‐1/PD‐L1 axis and promoted the infiltration of cytotoxic T cells. The co‐administration of CRLPs and BRLPs successfully delivered drugs to bone marrow, leading to significant modulation of the myeloma microenvironment, reduced tumor growth, and improved survival time of MM‐bearing mouse models. These findings introduced an alternative approach to modulating the myeloma microenvironment and underscored the efficacy of hitchhiking neutrophils for bone marrow drug delivery. This strategy show advantages over traditional drug delivery methods in terms of improved efficacy and lowered toxicity.https://doi.org/10.1002/advs.202409895bone marrow targetingc(RGDfk)liposomesmultiple myelomaneutrophil hitchhiking
spellingShingle Huiwen Liu
Bo Zhang
Hongrui Chen
Honglan Wang
Xifeng Qin
Chunyan Sun
Zhiqing Pang
Yu Hu
Targeted Delivery of c(RGDfk)‐Modified Liposomes to Bone Marrow Through In Vivo Hitchhiking Neutrophils for Multiple Myeloma Therapy
Advanced Science
bone marrow targeting
c(RGDfk)
liposomes
multiple myeloma
neutrophil hitchhiking
title Targeted Delivery of c(RGDfk)‐Modified Liposomes to Bone Marrow Through In Vivo Hitchhiking Neutrophils for Multiple Myeloma Therapy
title_full Targeted Delivery of c(RGDfk)‐Modified Liposomes to Bone Marrow Through In Vivo Hitchhiking Neutrophils for Multiple Myeloma Therapy
title_fullStr Targeted Delivery of c(RGDfk)‐Modified Liposomes to Bone Marrow Through In Vivo Hitchhiking Neutrophils for Multiple Myeloma Therapy
title_full_unstemmed Targeted Delivery of c(RGDfk)‐Modified Liposomes to Bone Marrow Through In Vivo Hitchhiking Neutrophils for Multiple Myeloma Therapy
title_short Targeted Delivery of c(RGDfk)‐Modified Liposomes to Bone Marrow Through In Vivo Hitchhiking Neutrophils for Multiple Myeloma Therapy
title_sort targeted delivery of c rgdfk modified liposomes to bone marrow through in vivo hitchhiking neutrophils for multiple myeloma therapy
topic bone marrow targeting
c(RGDfk)
liposomes
multiple myeloma
neutrophil hitchhiking
url https://doi.org/10.1002/advs.202409895
work_keys_str_mv AT huiwenliu targeteddeliveryofcrgdfkmodifiedliposomestobonemarrowthroughinvivohitchhikingneutrophilsformultiplemyelomatherapy
AT bozhang targeteddeliveryofcrgdfkmodifiedliposomestobonemarrowthroughinvivohitchhikingneutrophilsformultiplemyelomatherapy
AT hongruichen targeteddeliveryofcrgdfkmodifiedliposomestobonemarrowthroughinvivohitchhikingneutrophilsformultiplemyelomatherapy
AT honglanwang targeteddeliveryofcrgdfkmodifiedliposomestobonemarrowthroughinvivohitchhikingneutrophilsformultiplemyelomatherapy
AT xifengqin targeteddeliveryofcrgdfkmodifiedliposomestobonemarrowthroughinvivohitchhikingneutrophilsformultiplemyelomatherapy
AT chunyansun targeteddeliveryofcrgdfkmodifiedliposomestobonemarrowthroughinvivohitchhikingneutrophilsformultiplemyelomatherapy
AT zhiqingpang targeteddeliveryofcrgdfkmodifiedliposomestobonemarrowthroughinvivohitchhikingneutrophilsformultiplemyelomatherapy
AT yuhu targeteddeliveryofcrgdfkmodifiedliposomestobonemarrowthroughinvivohitchhikingneutrophilsformultiplemyelomatherapy